Mark Foletta - DexCom Independent Director
| DXCM Stock | USD 134.00 2.48 1.89% |
Director
Mr. Mark G. Foletta, CPA., serves as Lead Independent Director of DexCom Inc. Mr. Foletta has served on our Board since November 2014 and has served as our Lead Independent Director since November 2015. Mr. Foletta was the Chief Financial Officer and Executive Vice President of Tocagen, Inc. since February 2017. Mr. Foletta previously served as Senior Vice President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc., a publicly traded pharmaceutical company, from March 2006 through Amylins acquisition by Bristol MyersSquibb Company in August 2012, and as Vice President, Finance and Chief Financial Officer of Amylin from 2000 to 2006. Prior to joining Amylin in 2000, Mr. Foletta held a number of management positions with Intermark, Inc. and Triton Group Ltd. from 1986 to 2000 and served as an Audit Manager with Ernst Young. Mr. Foletta is currently a member of the Board of Directors and Audit Committee of AMN Healthcare Services, Inc., a publicly traded healthcare workforce solutions provider. From August 2015 to July 2016, Mr. Foletta served as the interim CFO of Biocept, Inc., an early commercialstage publicly traded molecular oncology diagnostics company. Mr. Foletta is also on the Board of Directors of Viacyte, Inc., a private biotechnology company. Mr. Foletta received a B.A. in Business Economics from the University of California, Santa Barbara and is a member of the Corporationrationrate Directors Forum. Mr. Folettas considerable audit and financial experience in the biotechnology and pharmaceutical sectors qualifies him to serve on the Board. since 2015.
| Age | 57 |
| Tenure | 9 years |
| Professional Marks | CPA |
| Address | 6340 Sequence Drive, San Diego, CA, United States, 92121 |
| Phone | 858 200 0200 |
| Web | https://www.dexcom.com |
DexCom Management Efficiency
The company has return on total asset (ROA) of 0.0641 % which means that it generated a profit of $0.0641 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2578 %, meaning that it created $0.2578 on every $100 dollars invested by stockholders. DexCom's management efficiency ratios could be used to measure how well DexCom manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of April 2024, Return On Tangible Assets is likely to grow to 0.09. Also, Return On Capital Employed is likely to grow to 0.13. At this time, DexCom's Intangible Assets are very stable compared to the past year. As of the 24th of April 2024, Return On Tangible Assets is likely to grow to 0.09, while Debt To Assets are likely to drop 0.41.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Michael Leavitt | HealthEquity | 66 | |
| Frank Medici | HealthEquity | 53 | |
| Thompson Dent | HealthStream | 68 | |
| Debra McCowan | HealthEquity | 46 | |
| JoAnn Martin | National Research Corp | 63 | |
| Linda Rebrovick | HealthStream | 62 | |
| Kjersti Kanne | National Research Corp | N/A | |
| John Nunnelly | National Research Corp | 65 | |
| Harald Arnet | National Research Corp | N/A | |
| Gayle Wellborn | HealthEquity | 56 | |
| Frank Gordon | HealthStream | 55 | |
| Deborah Tate | HealthStream | 61 | |
| P Shastri | National Research Corp | 65 | |
| Barbara Mowry | National Research Corp | 70 | |
| Savita Acharya | National Research Corp | 41 | |
| Dale Polley | HealthStream | 67 | |
| Evelyn Dilsaver | HealthEquity | 62 | |
| Martiny Harris | HealthStream | 59 | |
| Donald Berwick | National Research Corp | 71 | |
| Michael Shmerling | HealthStream | 62 | |
| William Stead | HealthStream | 69 | |
Management Performance
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.0641 |
DexCom Inc Leadership Team
Elected by the shareholders, the DexCom's board of directors comprises two types of representatives: DexCom inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DexCom. The board's role is to monitor DexCom's management team and ensure that shareholders' interests are well served. DexCom's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DexCom's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Eric Topol, Independent Director | ||
| Lanny Roper, CFO, Vice President | ||
| Shelly Selvaraj, Senior Officer | ||
| Matthew Dolan, Corporate Strategy | ||
| Patrick Murphy, Chief Compliance Officer, Vice President General Counsel | ||
| Mark Foletta, Independent Director | ||
| Jonathan Lord, Independent Chairman of the Board | ||
| Jacob Leach, Executive COO | ||
| Donald Abbey, Executive Vice President Quality and Information Technology | ||
| Jay Skyler, Independent Director | ||
| Jake Leach, Senior Vice President of Research and Development | ||
| Jorge Valdes, Chief Technical Officer and Executive VP | ||
| Paul Flynn, Ex Revenue | ||
| Kevin Sayer, CEO and President and Director | ||
| Terrance Gregg, Executive Chairman | ||
| Michael Brown, Executive Officer | ||
| Richard Doubleday, Senior Vice President - Worldwide Sales and Marketing | ||
| Jess Roper, CFO and Sr. VP | ||
| Sean Christensen, Director Relations | ||
| Quentin Blackford, CFO | ||
| Kevin Sun, Interim CFO | ||
| Nicholas Augustinos, Independent Director | ||
| Leverne Marsh, Executive Marketing | ||
| Jeffrey Moy, Senior Vice President - Operations | ||
| Jereme Sylvain, CFO VP | ||
| Heather Ace, Senior Vice President Human Resources | ||
| Girish Naganathan, Executive CTO | ||
| John Lister, Senior Vice President General Counsel | ||
| Richard Collins, Independent Director | ||
| Sadie Stern, Executive Officer | ||
| Barbara Kahn, Independent Director | ||
| Steven Pacelli, Executive VP of Strategy and Corporate Devel. | ||
| Andrew Balo, Senior Vice President - Clinical and Regulatory Affairs | ||
| Steven Altman, Independent Director |
DexCom Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DexCom a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.0641 | ||||
| Profit Margin | 0.15 % | ||||
| Operating Margin | 0.21 % | ||||
| Current Valuation | 50.26 B | ||||
| Shares Outstanding | 385.52 M | ||||
| Shares Owned By Insiders | 0.40 % | ||||
| Shares Owned By Institutions | 99.60 % | ||||
| Number Of Shares Shorted | 14.57 M | ||||
| Price To Earning | 245.31 X |
Pair Trading with DexCom
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DexCom position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DexCom will appreciate offsetting losses from the drop in the long position's value.Moving against DexCom Stock
| 0.81 | DH | Definitive Healthcare Financial Report 2nd of May 2024 | PairCorr |
| 0.79 | SIBN | Si Bone Financial Report 6th of May 2024 | PairCorr |
| 0.74 | SRDX | SurModics Earnings Call This Week | PairCorr |
| 0.73 | LNSR | LENSAR Inc | PairCorr |
| 0.72 | BWAY | Brainsway Financial Report 15th of May 2024 | PairCorr |
The ability to find closely correlated positions to DexCom could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DexCom when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DexCom - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DexCom Inc to buy it.
The correlation of DexCom is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DexCom moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DexCom Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DexCom can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the DexCom Inc information on this page should be used as a complementary analysis to other DexCom's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for DexCom Stock analysis
When running DexCom's price analysis, check to measure DexCom's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DexCom is operating at the current time. Most of DexCom's value examination focuses on studying past and present price action to predict the probability of DexCom's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DexCom's price. Additionally, you may evaluate how the addition of DexCom to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |
Is DexCom's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.81 | Earnings Share 1.29 | Revenue Per Share 9.384 | Quarterly Revenue Growth 0.269 | Return On Assets 0.0641 |
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.